Dr Scott Gottlieb Chosen to Head the FDA
President Donald Trump is expected to name Scott Gottlieb, MD, a resident scholar with the American Enterprise Institute, to lead the FDA, according to reports. Gottlieb would replace Robert Califf, MD, who only took over the position February 2016 and stepped down less than a year later in January 2017.
Updated March 13, 2017 at 2:06 pm
President Donald Trump
Gottlieb has previously worked for the FDA as deputy commissioner of medical and scientific affairs. However, he has expressed opposition to many regulations at the agency, which could cause Democrats to
Public Citizen has come out strongly against Gottlieb. Michael Carome, MD, director of Public Citizen's Health Research Group, cited Gottlieb's ties to industry as a reason why the Senate should not confirm him.
Gottlieb’s appointment would accelerate a decades-long trend in which agency leadership too often makes decisions that are aligned more with the interests of industry than those of patients," Carome
"
Gottlieb has a history of working with The American Journal of Managed Care®. He was the moderator for the
As a Forbes contributor, Gottlieb has written plenty on topics that
"Enabling drugs prices to more accurately reflect the value they deliver to individual patients will also require FDA to change its own rules,"
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- More Effective CKD Strategy Could Have Health, Societal Benefits
September 22nd 2025
- Antifibrotic Therapy Effective for Certain Patients With PPF
September 22nd 2025